LianBio (LIAN)

Overview

LianBio is a biopharmaceutical entity focusing on the development and commercialization of innovative medicines aimed at the markets within China and other Asian countries. Its primary therapeutic areas include cardiovascular, oncology, ophthalmology, and inflammatory diseases. The company prides itself on a diversified pipeline of drugs aimed at addressing some of the most challenging medical conditions. Established in 2019, LianBio is strategically headquartered in Princeton, New Jersey, underscoring its global outlook while focusing on the Asian pharmaceutical landscape. Through strategic partnerships, such as those with Tarsus Pharmaceuticals, Inc. for the development of TP-03 and with Nanobiotix S.A. for NBTXR3, LianBio leverages collaborative efforts to advance its mission of bringing breakthrough treatments to market.

Products and Services

• Mavacamten - Developed for treating obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction. This candidate represents LianBio's commitment to addressing complex cardiovascular diseases.
• TP-03 - This ophthalmic solution is targeted at treating Demodex blepharitis and meibomian gland disease, underlining the company's venture into eye health. LianBio partners with Tarsus Pharmaceuticals, Inc. to commercialize this promising treatment.
• NBTXR3 - A novel radioenhancer designed to be injected into malignant tumors before radiotherapy for head and neck squamous cell carcinoma and other solid tumors. It showcases LianBio's innovative approach to oncology, developed in partnership with Nanobiotix S.A.
• Infigratinib - Focused on cholangiocarcinoma and gastric cancers, Infigratinib is developed for both second-line and first-line treatments, reflecting LianBio's dedication to transforming cancer care.
• BBP-398 - A targeted therapy for solid tumors, demonstrating LianBio's involvement in the oncology sector with a focus on precision medicine.
• Omilancor and NX-13 - These two distinct compounds are geared towards the treatment of ulcerative colitis and Crohn's disease, showcasing LianBio's pursuit of solutions in the sphere of inflammatory diseases.
• LYR-210 - Tailored for chronic rhinosinusitis, LYR-210 represents the company's venture into solutions for respiratory conditions, aiming at a sustained-release treatment.
• Sisunatovir - Addressing respiratory syncytial virus, this candidate illustrates LianBio's foray into infectious diseases, potentially offering new hope for patients, especially during seasonal outbreaks.